Author Archives: donttradeourlivesaway

High Court rejects AstraZeneca’s diabetes drug plea

Source: The Economic Times MUMBAI: The Delhi High Court has dismissed AstraZeneca’s plea to block Hyderabad based Lee Pharma from making copies of its anti-diabetes drug Onglyza and left it for the patent office to decide whether to grant a compulsory … Continue reading

Posted in Compulsory Licensing, Indian Patent Law, TRIPS flexibilities | Leave a comment

Decision Time On Biologics Exclusivity: Eight Years Is No Compromise

Source: IP Watch 30 July 2015 As the Trans-Pacific Partnership (TPP) negotiations approach their endgame, biologics exclusivity is still considered “one of the most difficult outstanding issues in the negotiation.”[2] Pharmaceutical companies seek longer data and marketing exclusivities to further delay … Continue reading

Posted in Biologics, data exclusivity, Trans-Pacific Partnership Agreement | Leave a comment

Secrecy and costs threaten benefits in momentous trade deal

Source: The Sydney Morning Herald 30 July 2015 Voters will not tolerate a shift in power from their elected governments to multinationals, placing foreign corporate interests above domestic ones. Federal Trade Minister Andrew Robb and officials from 11 nations are … Continue reading

Posted in Trans-Pacific Partnership Agreement | Leave a comment

UNAIDS calls on trade negotiators to uphold governments’ commitments to public health and access to medicines

Source: UNAIDS 30 July 2015 GENEVA, 28 July 2015—As the world celebrates the achievement of reaching 15 million people with HIV treatment and commits to ending the AIDS epidemic by 2030, UNAIDS reminds countries of the urgent need to ensure … Continue reading

Posted in Trans-Pacific Partnership Agreement, TRIPS flexibilities, TRIPS plus | Leave a comment

TPP enters final negotiations

Source: NZHerald A controversial trade deal between New Zealand and other Pacific Rim countries including the United States enters final negotiations this week. Prime Minister John Key said there would be “give and take” in the final negotiations of the … Continue reading

Posted in Trans-Pacific Partnership Agreement | Leave a comment

India’s IPR Policy to fully protect patents: Nirmala Sitharaman

Source: Business Standard 25 July 2015 The final draft of the National IPR Policy has been circulated for inter-ministerial consultation and is likely to be put up to the Union Cabinet for approval soon National IPR Policy, which is currently … Continue reading

Posted in IPR policy, TRIPS plus | Leave a comment

Gilead Limits Enrollment in its Hep C Patient Program to Pressure Insurers

Source: WSJ 21 July 2015 In a bid to push back against payers, Gilead Sciences is limiting enrollment to its patient assistance program for hepatitis C drugs, which helps people obtain the Sovaldi and Harvoni treatments when they lack sufficient … Continue reading

Posted in access to medicines, Hepatitis - C, Sofosbuvir | Leave a comment